Biocity Biopharmaceutics Co., Ltd.
12
4
5
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
8%
1 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Role: lead
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
Role: lead
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
Role: collaborator
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Role: lead
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
Role: lead
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
Role: lead
BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
Role: lead
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Role: lead
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Role: lead
Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
Role: lead
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Role: lead
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Role: lead
All 12 trials loaded